Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism (Q57218945)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21730210%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

title

Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21730210%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

0 references

1 reference

secondary hyperparathyroidism

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21730210%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Masafumi Fukagawa

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21730210%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

4

Akira Fujimori

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21730210%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

3

Shohei Nakanishi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21730210%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Masahiro Koizumi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21730210%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

English

0 references

publication date

5 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21730210%20AND%20SRC:MED&resulttype=core&format=json

Nephrology Dialysis Transplantation

6 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21730210%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21730210%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21730210%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

784-790

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21730210%20AND%20SRC:MED&resulttype=core&format=json

Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: baseline data from the MBD-5D.

6 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

FGF23-parathyroid interaction: implications in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Endocrine functions of bone in mineral metabolism regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

The parathyroid is a target organ for FGF23 in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Interpretation of serum calcium in patients with abnormal serum proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Phosphate and the parathyroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

Is the volume of the parathyroid gland a predictor of Maxacalcitol response in advanced secondary hyperparathyroidism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR384

21 January 2018

Identifiers

DOI

10.1093/NDT/GFR384

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21730210%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference